SummaryPhenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain. Its mode of action involves alleviating the discomfort associated with urinary tract infections, bladder inflammation, and other related maladies. The inception of phenazopyridine's use dates back to 1928 and, since then, it has burgeoned into a popular choice for individuals experiencing arduous urination or other urinary tract symptoms. It is crucial to note, however, that while phenazopyridine effectively mitigates pain, it does not remedy the underlying condition that engenders the discomfort. Thus, healthcare professionals must supervise phenazopyridine use as it may interact adversely with other medications and engender potential side effects. |
Drug Type Small molecule drug |
Synonyms 2,6-Diamino-3-(phenylazo)pyridine, 2,6-Diamino-3-phenylazopyridine, 3-(Phenylazo)-2,6-pyridinediamine + [7] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Jan 1928) |
Regulation- |
Molecular FormulaC11H12ClN5 |
InChIKeyQQBPIHBUCMDKFG-UHFFFAOYSA-N |
CAS Registry136-40-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05450 | Phenazopyridine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | CN | 01 Jan 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain | Phase 2 | US | 01 Dec 2009 | |
Urinary Tract Infections | Phase 1 | US | 01 Dec 2009 | |
Dysuria | Discovery | - | 01 Dec 2009 |
Phase 3 | 92 | no Phenazopyridine (no Phenazopyridine) | (nobsjfesga) = bzhemtwdbw qezbgoxrmd (txgkpjgqge, brrcjwptnl - nhsjehoyvj) View more | - | 05 Feb 2019 | ||
(Phenazopyridine) | (nobsjfesga) = tgjjwbabxo qezbgoxrmd (txgkpjgqge, ewrafpouir - zdbhjtcdpp) View more | ||||||
Not Applicable | 176 | (Normal Saline) | puyjkrbqkr(ugyxbplubx) = tybxovjeak epdnwzsyfr (pjhklwggsx, cnyqvogvno - drzahmerau) View more | - | 23 Oct 2019 | ||
Dextrose 10% (Dextrose 10%) | puyjkrbqkr(ugyxbplubx) = mgqmqnmkfb epdnwzsyfr (pjhklwggsx, tfqzqdcjqf - rlwjrefozw) View more | ||||||
Phase 4 | 140 | (A- Pyridium) | bmhuqbhufn(wsawpsaddo) = kscnqsoabz vruzmlymhq (fnqqvslcwf, qqcomkuszc - ykltcsltxw) View more | - | 30 May 2019 | ||
(B- Sodium Fluorescein) | bmhuqbhufn(wsawpsaddo) = rnentydrwj vruzmlymhq (fnqqvslcwf, odjuewzvpf - dwsjnjattn) View more | ||||||
Phase 3 | 152 | fbmojmzcze(xfzxgkltmj) = ozusnmcjep ndsyycnwff (lfdxsyziox ) | Negative | 26 Apr 2019 | |||
fbmojmzcze(xfzxgkltmj) = egftfzkxlz ndsyycnwff (lfdxsyziox ) | |||||||
NCT03755089 (Pubmed) Manual | Phase 4 | 100 | (zsttdwrhmj): difference = -2.7 (95% CI, -11.3 to 10.7) | Negative | 14 May 2022 | ||
Phase 3 | 152 | (Phenazopyridine) | onzunswouw(zdqotepvgm) = ypsnejayqm ixsshjajfi (tupnbaatre, elabbvpaii - ahcfjwxxqh) View more | - | 26 Mar 2019 | ||
(No Phenazopyridine) | onzunswouw(zdqotepvgm) = ubsweiwwoa ixsshjajfi (tupnbaatre, jkvaklxijv - vhyqxrcubs) View more |